• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

美国南部育龄妇女中，在卡博特韦/利匹韦林获批时代对长效注射用抗逆转录病毒疗法的兴趣和偏好。

Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine Among Reproductive-aged Women in the US South.

作者信息

Collins Lauren F, Sheth Anandi N, Tisdale Tina, Mehta C Christina, Daniel Gaea, Westreich Daniel, Kassaye Seble, Topper Elizabeth F, Konkle-Parker Deborah, Rana Aadia, Alcaide Maria L, Philbin Morgan M

机构信息

Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

Ponce de Leon Center, Grady Health System, Atlanta, Georgia, USA.

出版信息

Clin Infect Dis. 2025 Feb 5;80(1):164-167. doi: 10.1093/cid/ciae331.

DOI:10.1093/cid/ciae331
PMID:38943370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11797392/
Abstract

Among 103 reproductive-aged women with human immunodeficiency virus (HIV) in the US South surveyed post-approval of long-acting injectable (LAI) cabotegravir/rilpivirine, nearly two-thirds reported willingness to try LAI antiretroviral therapy (ART). Most expressed preference for LAI over daily oral ART and had minimal concerns over potential LAI-ART use impacting reproductive health.

摘要

在美国南部对103名感染人类免疫缺陷病毒（HIV）的育龄妇女进行的调查中，这些妇女是在长效注射用卡博特韦/利匹韦林获批后接受调查的，近三分之二的人表示愿意尝试长效注射抗逆转录病毒疗法（ART）。大多数人表示比起每日口服抗逆转录病毒疗法，更喜欢长效注射疗法，并且对长效注射抗逆转录病毒疗法的使用可能影响生殖健康的担忧微乎其微。

相似文献

1
Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine Among Reproductive-aged Women in the US South.美国南部育龄妇女中，在卡博特韦/利匹韦林获批时代对长效注射用抗逆转录病毒疗法的兴趣和偏好。
Clin Infect Dis. 2025 Feb 5;80(1):164-167. doi: 10.1093/cid/ciae331.
2
Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.佛罗里达州卫生保健提供者和 HIV 感染者对长效注射用卡替拉韦/利匹韦林用于抗逆转录病毒治疗实施情况的看法。
AIDS Patient Care STDS. 2024 Jun;38(6):275-285. doi: 10.1089/apc.2024.0067. Epub 2024 Apr 30.
3
Brief Report: Stated Preferences for Long-Acting Injectable ART Among Mobile Men Living With HIV in Malawi: A Qualitative Study.简短报告：马拉维感染艾滋病毒的流动男性对长效注射抗逆转录病毒治疗的既定偏好：一项定性研究。
J Acquir Immune Defic Syndr. 2024 Dec 15;97(5):e25-e29. doi: 10.1097/QAI.0000000000003525.
4
Comparison of At-Home Versus In-Clinic Receipt of Long-Acting Injectable Cabotegravir/Rilpivirine.长效注射用卡博特韦/利匹韦林居家给药与门诊给药的比较。
Clin Infect Dis. 2025 Mar 17;80(3):613-617. doi: 10.1093/cid/ciae472.
5
Long-Acting Injectable Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus: A Review.长效注射用抗逆转录病毒疗法治疗人类免疫缺陷病毒：综述
Curr HIV/AIDS Rep. 2025 Apr 23;22(1):31. doi: 10.1007/s11904-025-00741-4.
6
Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis.长效卡博特韦加rilpivirine对HIV病毒血症患者的疗效：一项系统评价和荟萃分析。
HIV Med. 2025 Apr 9. doi: 10.1111/hiv.70025.
7
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.长效注射用卡博特韦与长效注射用利匹韦林联合用于病毒学抑制的青少年HIV感染者的安全性研究（IMPAACT 2017/MOCHA）：一项1/2期、多中心、开放标签、非对照、剂量探索性研究
Lancet HIV. 2025 Mar;12(3):e191-e200. doi: 10.1016/S2352-3018(24)00344-8.
8
PrEP15-19 Choices: an implementation study protocol of HIV prevention with oral and long-acting injectable cabotegravir PrEP in real-word settings among sexual and gender minority adolescents in Brazil.PrEP15 - 19选择：一项在巴西性少数和性别少数青少年的现实环境中使用口服和长效注射卡博特韦进行HIV预防的实施研究方案。
BMJ Open. 2025 Jan 20;15(1):e083146. doi: 10.1136/bmjopen-2023-083146.
9
The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.长效注射用卡替拉韦-利匹韦林在撒哈拉以南非洲治疗 HIV 的潜在作用：建模分析。
Lancet Glob Health. 2021 May;9(5):e620-e627. doi: 10.1016/S2214-109X(21)00025-5. Epub 2021 Mar 23.
10
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.在3b期SOLAR研究中，与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺相比，卡博特韦+利匹韦林长效维持治疗12个月后患者报告结局的改善情况。
AIDS Behav. 2025 Jan;29(1):64-76. doi: 10.1007/s10461-024-04490-0. Epub 2024 Oct 8.

引用本文的文献

1
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions.优化卡博特韦加rilpivirine长效疗法在HIV治疗中的应用：证据、实施及未解决的问题
Open Forum Infect Dis. 2025 Jul 3;12(7):ofaf368. doi: 10.1093/ofid/ofaf368. eCollection 2025 Jul.
2
The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections.利匹韦林探寻治疗HIV感染神奇药物的曲折之路。
Viruses. 2025 Jul 8;17(7):959. doi: 10.3390/v17070959.
3
Perceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy.注射吸毒者对用于阿片类物质使用障碍、暴露前预防和抗逆转录病毒治疗的长效药物的看法。
Open Forum Infect Dis. 2025 Mar 6;12(3):ofaf120. doi: 10.1093/ofid/ofaf120. eCollection 2025 Mar.
4
Enhancing Hepatitis B Virus Vaccine Uptake and Immunity Through Long-Acting Antiretroviral Therapy Programmatic Synergy in the US South.通过长效抗逆转录病毒治疗方案协同作用提高美国南部地区乙型肝炎病毒疫苗接种率和免疫力
Open Forum Infect Dis. 2025 Feb 19;12(3):ofaf096. doi: 10.1093/ofid/ofaf096. eCollection 2025 Mar.
5
Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges.长效注射用卡博特韦/利匹韦林在有HIV且存在依从性挑战的人群中的应用。
Curr Opin HIV AIDS. 2025 Jan 1;20(1):11-18. doi: 10.1097/COH.0000000000000904. Epub 2024 Nov 8.

本文引用的文献

1
Likelihood of Trying Long-Acting Injectable Antiretroviral Therapy Among Women With HIV in Nine Sites Across the United States.美国九个地区感染艾滋病毒的女性尝试长效注射抗逆转录病毒疗法的可能性。
J Acquir Immune Defic Syndr. 2024 Jul 1;96(3):e23-e27. doi: 10.1097/QAI.0000000000003422.
2
Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV.长效注射用卡博特韦和利匹韦林用于一名感染艾滋病毒的孕妇
Clin Infect Dis. 2024 Dec 17;79(6):1468-1471. doi: 10.1093/cid/ciae242.
3
Centring the health of women across the HIV research continuum.将妇女健康置于艾滋病病毒研究连续体的中心。
Lancet HIV. 2024 Mar;11(3):e186-e194. doi: 10.1016/S2352-3018(24)00004-3.
4
Understanding Disparities in Antiretroviral Therapy Adherence and Sustained Viral Suppression Among Black, Hispanic/Latina, and White Women in the United States - Medical Monitoring Project, United States, 2015-2019.了解美国黑人和西班牙裔/拉丁裔以及白人女性在抗逆转录病毒治疗依从性和持续病毒抑制方面的差异 - 医疗监测项目，美国，2015-2019 年。
J Acquir Immune Defic Syndr. 2023 Aug 15;93(5):413-421. doi: 10.1097/QAI.0000000000003214.
5
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.在临床试验中，接受长效卡替拉韦和利匹韦林治疗的 HIV 感染孕妇的妊娠结局和药代动力学。
HIV Med. 2023 May;24(5):568-579. doi: 10.1111/hiv.13439. Epub 2022 Nov 21.
6
The risks associated with stopping injectable antiretroviral treatment in women who are trying to conceive: a case series.尝试受孕女性停止注射用抗逆转录病毒治疗的相关风险：病例系列
AIDS. 2022 Jul 1;36(8):1205-1206. doi: 10.1097/QAD.0000000000003236.
7
Study of Treatment and Reproductive Outcomes Among Reproductive-Age Women With HIV Infection in the Southern United States: Protocol for a Longitudinal Cohort Study.美国南部感染艾滋病毒的育龄妇女的治疗与生殖结局研究：一项纵向队列研究方案
JMIR Res Protoc. 2021 Dec 20;10(12):e30398. doi: 10.2196/30398.
8
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.长效卡替拉韦和利匹韦林每 2 个月给药 1 次用于治疗成人 HIV-1 感染（ATLAS-2M）：96 周结果：一项随机、多中心、开放性标签、3b 期、非劣效性研究。
Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11.
9
Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.长效注射型抗逆转录病毒药物治疗（ART）和暴露前预防（PrEP）在全美六城市的女性中的应用：谁将受益最大的定性分析。
AIDS Behav. 2022 Apr;26(4):1260-1269. doi: 10.1007/s10461-021-03483-7. Epub 2021 Oct 14.
10
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.长效卡博替拉韦加利匹韦林用于治疗成人 HIV-1 感染：随机、开放标签、3 期 FLAIR 研究的 96 周结果。
Lancet HIV. 2021 Apr;8(4):e185-e196. doi: 10.1016/S2352-3018(20)30340-4.